VIRON DEVELOPS NEW GENERATION POROSOME-TARGETING DRUGS TO TREAT CYSTIC FIBROSIS & TYPE 2 DIABETES

Viron Inc., using its proprietary porosome proteome platform technology, has developed novel therapy in treating Cystic Fibrosis, and a combinatorial drug therapy in the treatment of Type II Diabetes. While Viron’s Cystic Fibrosis therapy is based on a non-invasive replacement of a functional mucus-secreting machinery, its small molecule and porosome-proteom enhancement therapy, increases both the synthesis and glucose-stimulated secretion of insulin from beta cells of the endocrine pancreas.